Thursday, June 28, 2012
University of Pittsburgh School of Medicine researchers have shown that a compound derived from endostatin
prevented and reversed organ fibrosis in mice.1 The findings may suggest
a new use for endostatin, which is approved in China as an antiangiogenic agent
to treat cancer.
L. SciBX 5(26);
doi:10.1038/scibx.2012.671Published online June 28, 2012
1. Yamaguchi, Y. et al.
Sci. Transl. Med.; published online May 30, 2012; doi:10.1126/scitranslmed.3003421
Contact: Carol A. Feghali-Bostwick, University of Pittsburgh School of
Medicine, Pittsburgh, Pa.e-mail: firstname.lastname@example.org or email@example.com
Contact: Yukie Yamaguchi, same affiliation as above e-mail: firstname.lastname@example.org
Contact: Adriana T. Larregina, same affiliation as above e-mail: email@example.com
2. BioCentury 6(42),
A4; May 11, 1998
3. Sumi, M. et al. J.
Clin. Lab. Anal. 19, 146-149 (2005)
4. Hebbar, M. et al.
Arthritis Rheum. 43, 889-893 (2000)
AND INSTITUTIONS MENTIONED
Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland
Alchemgen Therapeutics Inc., Houston, Texas
Boston Children's Hospital, Boston, Mass.
EntreMed Inc. (NASDAQ:ENMD), Rockville, Md.
Simcere Pharmaceutical Group (NYSE:SCR), Nanjing, China
University of Pittsburgh School of Medicine, Pittsburgh, Pa.